Role of VEGF/VEGFR autocrine in mediating EGFR TKI resistance in non-small cell lung cancer

被引：1
|
作者：
Osude, Chike [1 ]
Lin, Leo [1 ]
Foster, Brad [1 ]
Puri, Neelu [1 ]
机构：
[1] Univ Illinois, Coll Med Rockford, Rockford, IL USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-2595
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2595
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Clinical targeting of VEGF and EGFR effective in non-small cell lung cancer
    不详
    CANCER BIOLOGY & THERAPY, 2004, 3 (07) : 588 - 589
  • [42] The Role of Surgical Resection of Advanced Non-Small Cell Lung Cancer after a Response to EGFR-TKI
    Chen, Y.
    Su, P.
    Chang, C.
    Yen, Y.
    Lin, C.
    Su, W.
    Tseng, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S623 - S624
  • [43] Activation of AURKA contributes to TKI resistance in EGFR-mutant non-small lung cancer
    Lee, Meng-Hsuan
    Hong, Shiao-Ya
    Kao, Yu-Rung
    Wu, Cheng-Wen
    CANCER RESEARCH, 2019, 79 (13)
  • [44] A role for stromal EGFR activation in resistance to VEGF blockade in human non-small cell lung cancer (NSCLC) xenograft models
    Cascone, Tina
    Herynk, Matthew
    Du, Danny
    Oborn, Carol
    Kadara, Humam
    Nilsson, Monique
    Lee, Ju-Seog
    Langley, Robert
    Heymach, John
    CANCER RESEARCH, 2009, 69
  • [45] Epiregulin confers EGFR-TKI resistance via EGFR/ErbB2 heterodimer in non-small cell lung cancer
    Ma, Shiqi
    Zhang, Lu
    Ren, Yuan
    Dai, Wei
    Chen, Tingqing
    Luo, Liping
    Zeng, Juan
    Mi, Kun
    Lang, Jinyi
    Cao, Bangrong
    ONCOGENE, 2021, 40 (14) : 2596 - 2609
  • [46] Epiregulin confers EGFR-TKI resistance via EGFR/ErbB2 heterodimer in non-small cell lung cancer
    Shiqi Ma
    Lu Zhang
    Yuan Ren
    Wei Dai
    Tingqing Chen
    Liping Luo
    Juan Zeng
    Kun Mi
    Jinyi Lang
    Bangrong Cao
    Oncogene, 2021, 40 : 2596 - 2609
  • [47] Utilizing a combined biomarker and therapeutic strategy to reverse TKI resistance in EGFR mutant non-small cell lung cancer
    O'Byrne, K. J.
    Adams, M. N.
    Richard, D. J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1017 - S1017
  • [48] The reversible resistance mechanisms of second generation EGFR-TKI, Dacomitinib, in non-small cell lung cancer.
    Haga, Yuya
    Tsutsumi, Yasuo
    CANCER SCIENCE, 2023, 114 : 1488 - 1488
  • [49] MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer
    Li, Bing
    Ren, Shengxiang
    Li, Xuefei
    Wang, Yongsheng
    Garfield, David
    Zhou, Songwen
    Chen, Xiaoxia
    Su, Chunxia
    Chen, Mo
    Kuang, Peng
    Gao, Guanghui
    He, Yayi
    Fan, Lihong
    Fei, Ke
    Zhou, Caicun
    Schmit-Bindert, Gerald
    LUNG CANCER, 2014, 83 (02) : 146 - 153
  • [50] The Role of Serine Protease 8 in Mediating Gefitinib Resistance in Non-small Cell Lung Cancer
    Gao, Hai-Jing
    Geng, Xue-Li
    Wang, Ling-Ling
    Zhao, Chun-Nan
    Liang, Zong-Ying
    Xing, En-Hong
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2024, 24 (18) : 1339 - 1346
12345